Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the FDA previously notified Concert that it was reviewing the Breakthrough Therapy designation previously granted for deuruxolitinib. At the FDA's request, Concert submitted additional clinical data an

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

Mizuho reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $9.00 from $13.00 previously

Truist reiterated coverage of Concert Pharmaceuticals with a rating of and set a new price target of $22.00 from $30.00 previously

Truist Securities reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $30.00 previously

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

15-12G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and business development in the biopharmaceutical and biotechnology industries. “We are pleased to welcome Nancy to our Board of Directors. Her experience at a broad range of companies from both a

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to be Presented at the World Congress for Hair Research Conference Call Scheduled Today at 8:30 a.m. ET; Registration Required to Join Live Call Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2022. "With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the

SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)